Permission sought for clinical trial of Globe’s vaccine

Staff Correspondent

18 January, 2021 12:00 AM printer

Globe Biotech Limited, the only Bangladeshi drug company that has developed a Covid-19 vaccine, has submitted a protocol to the Bangladesh Medical Research Council (BMRC) for ethical approval to conduct the clinical trial of their vaccine ‘Bangavax’.

On behalf of the pharmaceutical company, Clinical Research Organization (CRO), a private contract research organisation, submitted the

protocol on Sunday, said sources at Globe Biotech.

The Bangladeshi company can conduct human trial of the homegrown coronavirus vaccine in seven to 10 days after getting the approval to the protocol, the sources added.

Globe Biotech on December 28 received the approval from the Directorate General of Drug Administration (DGDA) for manufacturing its vaccine for a clinical trial.

At a press conference earlier on October 5 last, Md Harunur Rashid, chairman of Globe Pharmaceuticals Group of Companies, said they would go for a clinical trial to prove the effectiveness of their vaccine in human body.

Mentioning that they have already completed a three-month pre-clinical trial of the Covid-19 vaccine, he had said their vaccine was featured in international publications.

At the press conference, Kakon Nag, chief executive officer (CEO) of Globe Biotech Ltd, said their vaccine, initially named ‘BANCOVID’, showed high efficiency on mice during the pre-clinical trial.

On July 2 last year, Globe Biotech announced that they were developing a Covid-19 vaccine as they completed preliminary animal trials successfully.

The World Health Organization (WHO) also enlisted the vaccine developed by Globe Biotech. Globe Biotech has at first made a contract with the icddr,b to conduct the clinical trial of its coronavirus vaccine but they cancelled their agreement later.

It later assigned the Clinical Research Organization to run the trial of their mRNA vaccine.